Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Breast Cancer with Brain Metastases
NCT02260531Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2014
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in breast cancer (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: CNS Objective Response Rate at 25 months. Started Nov 2014; status: completed.
02
Drugs
cabozantinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02260531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260531.